Jun 04, 2020
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
May 07, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
Feb 10, 2020
Pharmacosmos Therapeutics Inc. established as a new specialty pharmaceutical company to bring recently approved treatment option to iron deficiency anemia patients
Jan 28, 2020
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
Jan 06, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
Dec 03, 2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
Nov 20, 2019
Carlos Pascoal Joins DPS Group as Director of Construction Management Projects
Oct 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
Oct 29, 2019
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Oct 29, 2019
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Aug 07, 2019
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
Jan 16, 2019
Protagonist Therapeutics Reports Granting of Inducement Award
Jan 09, 2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
Nov 07, 2018
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14
Oct 08, 2018
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting
Sep 24, 2018
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1
Sep 06, 2018
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
Sep 06, 2018
Protagonist Therapeutics Expands Intellectual Property Portfolio
Aug 17, 2018
Protagonist Therapeutics Reports Granting of Inducement Award
Jun 18, 2018
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting